Korea's First 'Unicorn Special Listing' Boronoi "Aiming for FDA Approval of 4 Therapeutics Within 5 Years After Listing"

Online Corporate Presentation Held on the 14th
Plan to Expand Clinical Pipeline to 20
Total of 4 Technology Transfers... Worth 2.1 Trillion KRW

Kim Dae-kwon, CEO of Voronoi, is conducting an online corporate presentation on the 14th.

[Asia Economy Reporter Lee Gwan-ju] Boronoi, which is set to enter the KOSDAQ market through Korea's first unicorn (market-valued outstanding company) special listing, has expressed its ambition to expand its pipeline to 20 within the next five years and develop four drugs approved by the U.S. Food and Drug Administration (FDA).

On the afternoon of the 14th, Boronoi held an online corporate briefing attended by CEO Kim Dae-kwon and key executives to introduce the company and outline its growth plans post-listing.

CEO Kim stated, "Even after listing, based on Boronoi's outstanding research and development capabilities and speed, we plan to expand our clinical pipeline to 20, including those developed by technology transfer partners, and continue technology exports to global major pharmaceutical companies. Our goal is to become the originator that receives accelerated FDA approval for four genotype-directed cancer treatments with clearly identified carcinogenic mutations within five years."

Founded in 2015, Boronoi develops targeted therapies that selectively bind only to disease-causing kinases among over 550 kinases responsible for intracellular signal transduction. CEO Kim explained, "Kinases can be likened to traffic lights inside and outside cells, and when these traffic lights malfunction, diseases such as cancer occur. Boronoi researches and develops kinase inhibitors that selectively attach only to the malfunctioning traffic light proteins to eliminate the cause of disease."

Boronoi solved the problem of existing inhibitors failing to precisely target only the mutant proteins causing cancer and instead affecting proteins responsible for normal functions, causing side effects, through its core technology called 'Kinase Profiling.' This involves experimental data on whether potential candidate substances bind to 468 kinase targets. Boronoi has built a global top-level database (DB) of over 4,000 compounds with diverse scaffolds. From the early stages of research and development, it utilized the DB to find substances that react with target proteins and are non-toxic, significantly enhancing selectivity.

Additionally, the company explained that through its advanced 'Boronomics' platform, which combines artificial intelligence (AI) and wet lab experiments, it derives pipelines three times faster than competitors within 1 to 1.5 years and has secured blood-brain barrier penetration technology that surpasses global competitors. In particular, Boronoi's EGFR mutant non-small cell lung cancer treatment achieves a blood-brain barrier penetration rate of 70-100%, significantly higher than global competitors, offering new treatment options for patients with brain metastases from lung cancer.

Since 2020, Boronoi has licensed out a total of four new drug candidates (pipelines), three overseas and one domestic. Notably, the cumulative milestone payments from three global technology exports reached $1.7905 billion, including ▲October 2020 EGFR Exon20 INS-targeted non-small cell lung cancer treatment (U.S. Auric Pharmaceuticals), ▲August 2021 DYRK1A autoimmune and degenerative brain disease treatment (U.S. Brickell Biotech), and ▲November 2021 MPS1-targeted breast cancer and other solid tumor treatments (U.S. Pyramid Biosciences).

Boronoi plans to offer a total of 2 million shares through this public offering. The expected offering price ranges from 50,000 to 65,000 KRW per share, with total proceeds estimated between 100 billion and 130 billion KRW. After a two-day demand forecast on the 14th and 15th, subscription will proceed on the 21st and 22nd, with a scheduled KOSDAQ listing on the 30th. The joint lead managers are Korea Investment & Securities and Mirae Asset Securities. Boronoi intends to use the funds raised through this offering for research and development expenses and operating capital to establish a foundation for sustainable growth capable of generating multiple pipelines annually.

This content was produced with the assistance of AI translation services.